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ABSTRACT 17 
Vancomycin-resistant Enterococcus faecium (VREfm) bloodstream infections are associated with 18 
high recurrence rates. This study used genome sequencing to accurately distinguish the 19 
frequency of relapse and reinfection in patients with recurrent E. faecium bacteremia, and to 20 
investigate strain relatedness in patients with apparent VREfm and vancomycin-susceptible E. 21 
faecium (VSEfm) mixed infection. A retrospective study was performed at the Cambridge 22 
University Hospitals NHS Foundation Trust (CUH) between November 2006 and December 2012. 23 
We analyzed the genomes of 44 E. faecium isolated from 21 patients (26 VREfm from 12 24 
patients with recurrent bacteremia, and 18 isolates from 9 patients with putative VREfm/VSEfm 25 
mixed infection). Phenotypic antibiotic susceptibility was determined using the Vitek2 26 
instrument. Genomes were compared with those for a further 263 E. faecium associated with 27 
bacteremia in patients at CUH over the same time period. Pairwise comparison of core genomes 28 
indicated that 10 (71%) episodes of recurrent VREfm bacteremia were due to reinfection with a 29 
new strain, with reinfection being more likely with increasing time between the two positive 30 
cultures. The majority (78%) of patients with a mixed VREfm and VSEfm infection had unrelated 31 
strains. More than half (59%) of study isolates were closely related to another isolate associated 32 
with bacteremia from CUH. This included 60% of isolates associated with re-infection, indicating 33 
acquisition in the hospital. This study provides the first high-resolution insights into recurrence 34 
and mixed infection by E. faecium, and demonstrates that reinfection with a new strain, often 35 
acquired from the hospital, is a driver of recurrence.  36 
 3 
INTRODUCTION 37 
Enterococcus faecium is an important cause of bloodstream infections in critically ill and 38 
immunocompromised patients (1), and ranks among the ten most common microorganisms 39 
associated with healthcare-associated infections in the United States (US) (2). Bacteremia 40 
caused by vancomycin-resistant enterococci is associated with increased mortality, costs of care 41 
and rates of recurrence compared to vancomycin-susceptible strains (3–5).  42 
 43 
Despite the establishment of linezolid and daptomycin as mainstay therapeutic agents for 44 
vancomycin-resistant E. faecium (VREfm) bacteremia since the early 2000s, recurrence remains 45 
a common clinical challenge with rates ranging from 3% to 25% (6–8). Following apparent 46 
clearance of infection, recurrent bacteremia can be explained by either relapsing infection with 47 
the same strain due to a persistent focus of infection, or reinfection with the same or a different 48 
strain. Differentiating between these scenarios is clinically relevant; relapsing infection requires 49 
investigation and interventions to deal with a persistent focus of infection, whilst reinfection is 50 
more likely to be associated with an underlying susceptibility that increases the risk of invasion 51 
due to breakdown of host immune defenses. Surprisingly little is known about the relative 52 
frequency of relapse versus reinfection in recurrent E. faecium bacteremia, with the literature 53 
limited to case reports (9–11) and case series predominantly containing patients with 54 
Enterococcus faecalis infection (12, 13).  55 
 56 
E. faecium bacteremia is polymicrobial in up to 35% of cases due to mixed infection with other 57 
bacterial genera or enterococcal species (14). Apparent mixed infection with VREfm and 58 
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vancomycin-susceptible E. faecium (VSEfm) has been reported in the context of in-vivo loss or 59 
gain of the van transposon by sub-populations of the same strain (15–17). However, whilst 60 
carriage of multiple strains of E. faecium is presumed to be common (18, 19), the frequency of 61 
mixed infection with different E. faecium strains is unknown. 62 
 63 
Whole-genome sequencing has demonstrated superior discriminatory power compared to 64 
traditional bacterial typing techniques such as pulsed-field gel electrophoresis (PFGE) or 65 
multilocus sequence typing (MLST) in epidemiological investigations and in studies of the 66 
population structure of E. faecium causing bacteremia at a local and national level (20–23). 67 
Here, we use genome sequencing to gain a better understanding of E. faecium bacteremia. 68 
Specifically, we investigated strain relatedness in patients with recurrent VREfm bacteremia, 69 
and in patients with apparent mixed bloodstream infection with VREfm and VSEfm. In addition, 70 
we compared the findings of genome sequencing with antibiotic resistance profile. 71 
 72 
RESULTS 73 
A retrospective review of patients at CUH between November 2006 and December 2012 74 
identified 231 patients with at least one episode of VREfm bacteremia. Of these, 14 patients had 75 
at least one episode of recurrence, giving an estimated recurrence rate of 6.1%. We identified 76 
twelve patients that had isolates from at least two episodes of VREfm bacteremia available for 77 
whole genome sequencing (see Table 1 for patient summary and Dataset S1 for individual 78 
isolate information).  Ten patients had one recurrence and two patients had two recurrences of 79 
bacteremia. To determine the genetic relatedness of isolates causing recurrence we identified 80 
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SNPs in the core genome based on mapping to a reference genome. Of the fourteen isolate 81 
pairs associated with a recurrent bacteremia, four (from four patients) were closely related (1-7 82 
SNPs, median 1.5 SNPs) to the isolate from the previous episode (Figure 1A, Table 1). This 83 
finding is highly indicative of relapse (or reinfection) with the same strain, based on a study that 84 
reported a genetic distance between E. faecium carried by the same person (within-host 85 
diversity) of 6 core SNPs (24). By contrast, 10 isolates (from ten patients) were more genetically 86 
distant from the isolate from the previous episode (25-368 SNPs, median 258 SNPs), which is 87 
consistent with reinfection by a different strain (Figure 1A, Table 1). The two patients with two 88 
recurrences of bacteremia had both an episode of relapse (pairwise SNP difference of 2 or 7 89 
SNPs, respectively), and an episode of reinfection with a new strain (25 or 309 SNPs, 90 
respectively) (Table 1). The SNPs acquired between the first and second isolate for the four 91 
genetically related isolate pairs were located in different genes in different patients (Table S1). 92 
The median time to first recurrence across the study population was 80 days (range 39 to 1578 93 
days), and the second episodes of recurrence occurred 36 and 168 days after the preceding 94 
bacteremia.  Comparison of the timing of recurrence with the genomic analyses indicated that 95 
all isolates from cases of relapse/reinfection with the same strain were isolated within 108 days 96 
of each other, whilst recurrences due to reinfection with a different strain were equally likely to 97 
occur within 108 days (5/10 episodes) and after 108 days (5/10).  98 
 99 
All twelve study patients with recurrent bacteremia had multiple co-morbidities that predispose 100 
to VREfm bacteremia (Table 1, Dataset S1). The most probable source for the bacteremia was 101 
defined for each case (Table 1). Mucosal translocation (n=7, with possible concurrent 102 
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intravascular catheter infection) and intravascular catheters (n=5) were the most common 103 
sources of bacteremia for the study patients. There was no clear difference identified between 104 
the sources of infection in patients with recurrence due to the same or different strains (Table 1, 105 
Table S2). The four episodes of recurrence due to the same strain were associated with 106 
presumed persistent intravenous catheter colonization and/or gut carriage (n=3), or failure to 107 
eradicate a persistent focus of infection (n=1, chronic pyelonephritis associated with kidney 108 
stones) (Table 1, Table S2). A central venous catheter was known to be retained between 109 
episodes of bacteremia in 2/10 cases with reinfection with a different strain, meaning that 110 
whole genome sequencing was able to refute these as being a persistent focus.  111 
 112 
The retrospective review of CUH patients also identified nine patients with putative mixed 113 
bloodstream infection with VREfm and VSEfm for whom both isolates were available for whole 114 
genome sequencing (Table 1).  Pairwise core genome comparison of the 9 VREfm/VSEfm pairs 115 
revealed that 7/9 (78%) patients had isolate pairs that were genetically distinct (median 217 116 
SNPs, range 70-381 SNPs) (Figure 1B), which is consistent with true mixed-strain infection. The 117 
most common source of infection for patients with true mixed infection was an intravascular 118 
catheter (4/7, 57%). The remaining 2 patients had isolates that were identical at the core 119 
genome level. Further analysis of the genetic content between these 2 pairs through 120 
comparison to the ResFinder database confirmed the variable presence of the vanRSHAXYZ 121 
genes, which encode vancomycin resistance. There was insufficient sequence adjacent to the 122 
vanA transposon in the genome assemblies to identify the genetic location of these genes, so 123 
differences in gene content between the VREfm and VSEfm in each pair were assessed. In one 124 
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isolate pair (Patient 16) the van genes had been lost together with 21 genes, including 7 genes 125 
best matched to a plasmid (based on BLAST), suggesting they may have been lost/gained 126 
together with part of a plasmid (Dataset S2). Two genes labelled as tetM and ermB were lost 127 
alongside the van genes in this patient, but both isolates retained a copy of tetM and ermB and 128 
so this may not have affected the wider antibiotic resistance phenotype (Figure 2). In the 129 
second isolate pair (Patient 21) an additional 14 genes had been lost with the van genes 130 
including five genes located adjacent in the genome (Dataset S2) suggesting that vanA was not 131 
gained/lost as part of a plasmid but may have moved as part of a smaller transposable element.  132 
 133 
We evaluated whether the phenotypic antibiotic resistance profile (antibiogram) to 11 drugs 134 
(excluding glycopeptides) could be used to distinguish between genetically related and distinct 135 
strains from the same patient (Figure 2). Of the 6 isolate pairs that were closely related in the 136 
two study collections, four had identical antibiograms, one varied by tetracycline resistance 137 
associated with gain/loss of the tetM gene, and one varied between susceptible and 138 
intermediate resistance to quinupristin-dalfopristin (Figure 2). Of the 17 strain pairs that were 139 
genetically different, three had identical antibiograms and the remainder had between 1 and 5 140 
(median 2) differences (Figure 2). The most variable antibiotic was tetracycline (10/17 pairs), 141 
followed by high-level resistance to streptomycin (n=7), and nitrofurantoin (n=6). Since 3/7 142 
identical antibiograms (43%) belonged to genetically distinct strains, this suggests that 143 
antibiogram does not reliably distinguish between genetically related and distinct strains from 144 
the same patient. However, more than one change in the antibiogram was only identified in 145 
genetically distinct strains (12/17 genetically distinct pairs).  146 
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 147 
The high rate of true mixed VREfm and VSEfm infection and recurrence with a new strain 148 
indicates carriage of multiple lineages or the acquisition of new strains over time. Healthcare 149 
settings are associated with the acquisition of E. faecium, and so we investigated CUH as a 150 
putative source by combining the 44 study E. faecium genomes with a further 263 E. faecium 151 
genomes associated with bloodstream infection in 263 patients at the same hospital over the 152 
same time period (2006-2012) (Figure S1). Taken together, 26 of the 44 study isolates were 153 
closely related to at least one CUH isolate (0-8 SNPs, median 3), including 3 isolates that were 154 
closely related to an isolate from another study patient. This included isolates from 6/7 patients 155 
infected with different VREfm and VSEfm strains and 6/10 patients with recurrence caused by 156 
different strains. The remaining isolates were between 12 and 86 SNPs (median 33 SNPs) from 157 
the closest genetic match.  158 
 159 
DISCUSSION 160 
This study represents the first use of whole genome sequencing in the context of E. faecium 161 
bacteremia to investigate the relative rates of relapse and reinfection in recurrent infections, 162 
and to study mixed infection with VREfm and VSEfm.  Although rates of recurrence vary in the 163 
literature, the estimated rate of 6.1% identified at CUH is within the range of those reported 164 
previously (6–8).  165 
 166 
We found that the majority of patients in our study had a recurrent VREfm bacteremia caused 167 
by reinfection with a new strain. This finding supports that of Cheng et al. which found 168 
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reinfection to be responsible for ~70% of recurrence based on PFGE, although the study focused 169 
primarily on E. faecalis (12). These reinfections could either be due to persistent carriage of a 170 
genetically distinct strain, or reinfection with a newly acquired strain. We found that at least 171 
60% of reinfections were caused by isolates that were genetically closely related to another 172 
bacteremia isolate from CUH, suggesting cross-transmission in the hospital. Additionally, the 173 
rates of cross-transmission found in this study are likely to be an underestimate, since 174 
asymptomatic gut carriage and the environment represent a large reservoir of VREfm and were 175 
not sampled in this study. These findings suggest that the emphasis on preventing recurrent 176 
VREfm bacteremia should be on infection control and minimizing periods of susceptibility to 177 
infection. Further studies will be required to elucidate the role of the environment, staff and 178 
patients as sources for these hospital acquisitions to improve infection control. 179 
 180 
The results of this study suggest that recurrence with the same strain may be related to time. 181 
Episodes of recurrence with the same strain were only identified up to 108 days apart, which 182 
concurs with findings by Baran et al. based on E. faecalis and E. faecium from a total of three 183 
patients (13). In contrast to our findings for same-strain recurrence, our study showed that 184 
bacteremic episodes due to reinfections with a distinct strain were roughly equally likely to 185 
occur within and after 108 days of each other, and as early as 57 days apart. Further work will 186 
be required using larger sample sizes from multiple centers to determine whether there is a 187 
true relationship between the relatedness of E. faecium strains causing recurrence and the time 188 
between episodes.  189 
 190 
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We also identified that the majority of patients with mixed VREfm and VSEfm bacteremia were 191 
infected with two genetically distinct strains. This differs from the finding by Cardenas et al. that 192 
four patients had closely related VREfm and VSEfm strains associated with bacteremia based on 193 
MLST (16). The true mixed infections in our study frequently varied in antibiotic resistance 194 
profiles. Whilst most cases of mixed VREfm and VSEfm would be detected during routine disc 195 
susceptibility testing, this variation in antibiotic resistance profiles could complicate treatment 196 
in cases that go undetected. Although the numbers are low in our study, it was interesting to 197 
note that true mixed VREfm and VSEfm infections were commonly suspected to originate from 198 
an intravascular source, suggesting that central venous catheters may become colonized with 199 
multiple strains of E. faecium.  200 
 201 
The results of our study suggest that antibiogram lacks accuracy in predicting the genetic 202 
relatedness of strains. The utility of antibiograms for determining the relatedness of E. faecium 203 
has not previously been evaluated, but our finding that a pair of identical strains could vary in 204 
their resistance to antibiotics is consistent with the fact that E. faecium has a highly mobile 205 
genome, with many resistance genes carried on mobile genetic elements.  206 
 207 
Our study may have implications on future evaluation of VREfm treatment efficacy. There are 208 
currently no randomized controlled trials to define the optimal antibiotic for the treatment of 209 
VREfm bacteremia. Current knowledge is based on retrospective observational studies 210 
comparing linezolid to daptomycin, where recurrent infection is often defined as one of the 211 
outcome measures in the absence of bacterial typing results (6, 8, 25). These studies imply that 212 
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early recurrence (often assessed at 30 or 60 days after treatment completion) is caused by true 213 
relapse (6, 8), or rely on phenotype such as identical antibiograms to infer relapse (25). Our 214 
results show that in the absence of prospective randomized studies or bacterial genotyping, one 215 
needs to question whether a recurrent infection is indeed due to ineffective therapy as opposed 216 
to underlying confounding from patient related factors conferring increased susceptibility to 217 
reinfection. Future studies should address this issue. 218 
 219 
This study has several limitations. We did not sequence multiple colonies from the same sample 220 
to assess diversity, meaning that apparent reinfections could have been mixed infections at the 221 
outset. The study samples were retrieved from frozen stock and it is not possible to know 222 
whether these were originally created from a single or multiple colonies. It is not possible to 223 
differentiate between relapse and reinfection by the same strain, introducing an element of 224 
uncertainty into our classification. The true level of mixed infection will be higher than we 225 
report here, since we only assessed patients with a VREfm and VSEfm mixed infection and 226 
analysed one colony of each from every bacteremic episode. Finally, the rate of recurrence 227 
identified here may be an underestimate since repeat cultures were not taken systematically.  228 
 229 
In conclusion, the findings of this study show that the majority of VREfm recurrences and mixed 230 
VREfm and VSEfm infections are due to different strains, and that antibiogram lacks accuracy in 231 
determining genetic relatedness. This has important implications for infection control as it 232 
highlights the importance of reducing cross-transmission in vulnerable patient groups. 233 
 234 
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MATERIALS AND METHODS 235 
A retrospective study was conducted at the Cambridge University Hospitals NHS Foundation 236 
Trust (CUH), a tertiary referral center in the United Kingdom with 1,170 beds and 350,000 237 
occupied-bed-days per year. The rate of vancomycin resistance in E. faecium bacteremia 238 
isolates at CUH is high (>60%), approaching rates reported in the US (2) and historical data from 239 
2001 suggests that 32.6% of patients at CUH in high-risk wards carry VRE (either E. faecium or E. 240 
faecalis) (26). 241 
 242 
All patients with VREfm bloodstream infection between November 2006 and December 2012 243 
were identified using the diagnostic microbiology laboratory database. These cases were 244 
evaluated to identify all patients with (i) recurrence of VREfm bloodstream infection, and/or (ii) 245 
putative mixed VREfm and VSEfm bloodstream infection. Recurrence was defined as a blood 246 
culture that was positive for VREfm taken >30 days after the index culture from a patient with 247 
intervening negative blood cultures and/or resolution of clinical signs of infection. Putative 248 
mixed VREfm and VSEfm infection was defined as the isolation of VREfm and VSEfm from the 249 
same blood culture or different cultures taken within 48 h of the index sample.  250 
 251 
Fourteen patients fulfilled the criterion for recurrence and 10 patients fulfilled the criterion for 252 
putative mixed VREfm and VSEfm infection, with no overlap of cases between the two. Seven of 253 
the patients had mixed infection with other bacterial species, as shown in Dataset S1. Cross-254 
referencing these 24 patients with the bacterial freezer archive identified 44 isolates from 21 255 
patients (12 patients with recurrence and 9 patients with mixed VREfm and VSEfm infection), 256 
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who were the basis for this study. Clinical data for the 21 cases were collected from paper and 257 
computerized medical records using a standardized proforma, including the suspected focus of 258 
infection, underlying comorbidities, and dates of positive and negative blood cultures. 259 
Neutropenia was defined as a polymorphonuclear leukocyte count of less than 500/l within 24 260 
hours of the onset of bacteremia. The focus of infection was defined based on clinical, 261 
radiological and microbiological features. Bacteremia was determined to be secondary to an 262 
intravascular device if i) a positive intravascular catheter tip semi-quantitative culture yielded 263 
more than 15 cfu of E. faecium with identical antibiogram as the blood culture isolate (definite), 264 
or ii) if no other focus of infection was identified in the presence of an intravascular catheter, 265 
and/or clinical signs of sepsis improved after line removal (probable). For neutropenic patients 266 
with no definite clinical focus, mucosal translocation was presumed to be the origin of the 267 
bacteremia based on the Centers for Disease Control and Prevention definition 268 
(http://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf). In cases of recurrent 269 
infection, a focus was considered persistent if there was an unresolved deep source of infection 270 
or if a potentially infected intravascular catheter was not removed between episodes of 271 
bacteremia. Ethical approval for the study was obtained from the local Research Ethics 272 
Committee (reference no. 13/EE/0044) and the need for informed consent was waived.  273 
 274 
Twenty-one of the 44 isolates had been sequenced previously (27). For the 23 new E. faecium 275 
isolates sequenced here, bacteria were cultured on Columbia Blood Agar (CBA, Oxoid) for 48 276 
hours at 37°C in air. Phenotypic antimicrobial susceptibility testing for all 44 isolates was 277 
performed using the Vitek2 instrument (bioMérieux, Marcy l’Etoile, France) with the AST-P607 278 
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card.  DNA was extracted using the QIAxtractor (QIAgen) and sequencing performed on an 279 
Illumina HiSeq2000. Sequence reads were assembled using Velvet and annotated using Prokka. 280 
The pangenome was estimated using Roary (28) with a 98% ID cut-off. The van gene in the two 281 
patients with genetically related VREfm and VSEfm was extracted from the Roary pan genome 282 
and compared to the vanA gene extracted from a vanA transposon (accession number M97297) 283 
and the vanB gene extracted from Aus0004 (accession number CP003351) using BLAST. The 284 
presence of antibiotic resistance genes was determined using an in-house curated version of the 285 
ResFinder database (genes listed in Dataset S3) (29) and ARIBA (https://github.com/sanger-286 
pathogens/ariba/wiki).  287 
 288 
Sequence data for an additional 263 E. faecium associated with bloodstream infection in 263 289 
patients at CUH between November 2006 and December 2012 and belonging to the hospital-290 
adapted clone of Clade A based on whole genome sequence analysis were taken from Raven et 291 
al. (27). These 263 genomes together with the 44 study genomes were mapped to E. faecium 292 
Aus0004 (ENA accession number CP003351) using SMALT 293 
(http://www.sanger.ac.uk/science/tools/smalt-0).  Mobile genetic elements (identified based 294 
on annotation and PHAST (30)) and recombination events (identified using Gubbins (31)) were 295 
removed to identify the core genome. A maximum likelihood tree was created using RAxML 296 
based on single nucleotide polymorphisms (SNPs) in the core genome. Pairwise SNP differences 297 
were calculated based on SNPs in the core genome.  298 
 299 
Accession numbers are listed in Dataset S1.  300 
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FIGURE LEGENDS 426 
Figure 1. Genetic relatedness of isolates from the same patient with recurrent bacteremia (A), 427 
or mixed infection with VREfm and VSEfm (B). A) Right hand side: Graph showing the pairwise 428 
core genome SNP difference between E. faecium isolates cultured from the same patient more 429 
than 30 days apart, and timing of episodes. Red indicates isolate pairs that were closely related 430 
(1-7 SNPs) based on genome sequence data. Left hand side: expansion of the area of the graph 431 
under 100 SNPs. B) Graph showing the pairwise core genome SNP difference between VREfm 432 
and VSEfm isolates cultured from the same patient within 48 hours.   433 
 434 
Figure 2. Comparison between strain similarity by genome sequence data and antibiogram. 435 
Left hand side indicates the strain relatedness based on genome sequence data, and the 436 
patient. Two patients with both relapse and reinfection occur twice in the list. Middle block 437 
indicates changes in antibiotic resistance (red, defined as a change from susceptible to resistant; 438 
green, defined as a change from resistant to susceptible; white, no change) between isolates 439 
from the same patient. 440 
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 Table 1. Clinical and isolate details for the patient cohort. 441 
* Patients with recurrence with a different strain for whom a central venous catheter was retained between episodes of bacteremia.  442 
** Age at time of first bacteremia  443 
*** Co-morbidities identified across all episodes of bacteremia in the study (breakdown by bacteremic episode in Dataset S1) 444 
# Number of SNPs based on mapping to a reference genome (E. faecium Aus0004) 445 
Abbreviations: Pt = patient, SOM = solid organ malignancy, HM = hematological malignancy, SCT = stem cell transplant, SOT = solid organ transplant, ESRD = 446 
end stage renal disease, DM = diabetes mellitus, LC = liver cirrhosis, MT = mucosal translocation, IV = intravascular, IA = intra-abdominal 447 
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Pt Age
** 
Gender Co-morbidities *** Number 
of 
isolates 
Presumptive source of infection Year 
of 
first 
isola
te 
Number of 
days 
Number of 
SNPs# 
Interpretation 
1st 2nd 3rd 1st to 
2nd 
2nd 
to 
3rd 
1st 
to 
2nd 
2nd 
to 
3rd 
1st 
to 
3rd 
R
ec
u
rr
en
ce
 
1 67 Male SOM 3 Urinary Urinary Urinary 2010 54 36 25 2 25 Reinfection/Relapse 
2 50 Male HM, SCT 2 MT/IV MT/IV - 2007 1578 - 234 - - Reinfection 
3* 56 Male HM 2 MT/IV MT/IV - 2009 61 - 268 - - Reinfection 
4* 24 Female Congenital neutropenia 3 IV MT/IV MT/IV 2012 108 168 7 311 309 Relapse/Reinfection 
5 44 Female SOT, ESRD, DM 2 IV Unknown - 2009 777 - 299 - - Reinfection 
6 42 Female Alcoholic liver disease 2 IV IV - 2009 215 - 282 - - Reinfection 
7 13 Male HM, SCT, ESRD 2 MT/IV IV - 2007 1484 - 232 - - Reinfection 
8 41 Female HM, SCT, ESRD 2 MT/IV MT/IV - 2011 57 - 64 - - Reinfection 
9 10 Female HM 2 IV MT/IV - 2010 80 - 1 - - Relapse 
10 0 Male HM 2 IV MT/IV - 2010 59 - 348 - - Reinfection 
11 15 Female HM 2 MT/IV MT/IV - 2010 39 - 1 - - Relapse 
12 39 Male HM 2 MT/IV MT/IV - 2012 104 - 282 - - Reinfection 
M
ix
ed
 V
R
E
fm
 &
 V
SE
fm
 13 59 Female SOM, HM 2 IV - - 2012 2 - 329 - - Genetically distinct 
14 72 Male SOM, HM 2 MT - - 2012 0 - 119 - - Genetically distinct 
15 62 Male HM, SCT 2 IV - - 2011 0 - 217 - - Genetically distinct 
16 50 Male HM, SCT 2 MT/IV - - 2009 0 - 0 - - Genetically related 
17 56 Male HM 2 IV - - 2008 0 - 18 - - Genetically distinct 
18 59 Male SOM 2 IA - biliary - - 2008 0 - 381 - - Genetically distinct 
19 63 Male HM, SOT 2 IV - - 2009 1 - 203 - - Genetically distinct 
20 19 Male HM, SCT 2 MT/IV - - 2010 0 - 154 - - Genetically distinct 
21 48 Female ESRD, LC 2 Lung and IA - - 2010 0 - 0 - - Genetically related 
